TenNor's Phase III antibiotic trial meets all primary endpoints

By Yahoo! Finance | Nov 18, 2024 at 12:17 PM EST

TenNor Therapeutics' Phase III trial of rifasutenizol for H. pylori infection successfully met primary endpoints, surpassing current treatment standards. The antibiotic showed high efficacy, safety, and tolerability, offering a promising solution amid rising antimicrobial resistance concerns.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.